Related News

• Why Is Eli Lilly (LLY) Getting A Bigger Role For Mounjaro? | 2026-08-30
  Eli Lilly (NYSE: LLY) received FDA approval for Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. The decision expands Mounjaro’s use beyond blood sugar control to include reduction of cardiovascular events in at-risk patients. Mounjaro is the first dual GIP and GLP-1 receptor agonist to gain this cardiovascular risk reduction indication. The approval increases Eli Lilly’s addressable patient pool and affects its competitive position in diabetes and...
• Dol-llys Hall: Co-operative living where we share 15-acre Georgian mansion | 2026-08-29
  Co-housing residents live in a Grade II listed mansion for the same price as a two-bed house.
• Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? | 2026-08-28
  On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveraging OmniAb’s specialized antibody discovery platform, the deal grants Lilly exclusive global rights to commercialize resulting candidates in exchange for an upfront payment, up to $370 million in […]
• Lilly's $9.94 Billion Mounjaro Franchise Wins a Heart-Risk Label | 2026-08-28
  The FDA decision expands Mounjaro beyond glucose control while strengthening its position against competing cardiovascular therapies.
• Eli Lilly Scores Major FDA Win for Weight Loss Drug | 2026-08-28
  Lilly just strengthened one of its biggest growth engines
• 4 stocks to watch on Friday: MRNA, GILD, JBLU, and LLY | 2026-08-28
  Stock market update: JetBlue, Gilead, Eli Lilly and Moderna in focus on Icahn stake move, FDA approvals and debt deal.
• Lilly wins FDA label expansion for Mounjaro to reduce cardiovascular risk | 2026-08-28
  Eli Lilly (LLY) stock gains as the FDA expands the label for its GLP-1 drug Mounjaro to cut stroke/heart attack risk in adults with type 2 diabetes.
• Is Eli Lilly Stock Outperforming the Dow? | 2026-08-28
  Outpacing the Dow over the past 12 months, Eli Lilly continues to receive a highly bullish outlook from Wall Street analysts, reflecting confidence in the company’s long-term prospects.
• Eli Lilly Clears Big Hurdle in Alzheimer's Fight | 2026-08-26
  A simpler diagnostic tool could widen Alzheimer's testing access
• Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs | 2026-08-26
  New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.

News source: finlight